Home > Products > Novel inhibitors

PD-L1-IN-1

  Cat. No.:  DC48176  
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.:
Chemical Name: PD-L1-IN-1
Formula: C21H23N5O2
M.Wt: 377.44
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
TITLE DOWNLOAD
MSDS_32067_DC48176
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC49130 PD-1/PD-L1-IN-23 PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice.
DC44154 PD-1/PD-L1-IN 3 PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
DC42714 BMS-8 BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].
DC12058 BMS-1166 (PD-1/PD-L1-IN1) BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.
DC73542 YPD-29B YPD-29B is a potent, specific programmed cell death ligand 1 (PD-L1) inhibitor, effectively blocks the binding of PD-1 and PD-L1 with IC50 of 0.08 pM in HTRF protein-protein interaction assays.
DC73541 MAX10181 MAX10181 (MAX-10181) is an orally active small molecule PD-L1 inhibitor, shows similar efficacy as Durvalumab in the head to head test of human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice.
DC73540 IMMH-010 maleate IMMH-010 maleate (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.
DC73539 IMMH-010 IMMH-010 (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.
DC73538 BMS136 BMS136 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 96.7 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.
DC73537 BMS135 BMS135 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 79.1 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia